PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Reweighted MRC-ICU 2.0 Improves Complexity-Based Outcome Prediction

MRC-ICUmedication regimen complexitycritical careICUpharmacist workloadmachine learningpredictive modelingAPACHE IISOFAmedication safetyobservational cohort Clinical Pharmacy Practice

Background Information

MRC-ICU 2.0 boosts prediction accuracy for ICU outcomes.

Medication regimen complexity in the Intensive Care Unit (ICU) can impact patient outcomes and pharmacist workload, necessitating improved predictive models. The updated MRC-ICU 2.0 score demonstrated improved predictive ability over the original, with Area Under the Receiver Operating Characteristic (AUROC) increases of +0.03 to +0.08. MRC-ICU 2.0 offers complementary predictive value to severity-of-illness scores like Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA), enhancing decision-making in critical care. MRC-ICU 2.0 improves medication regimen complexity prediction and adds value when combined with other assessment tools in the ICU.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Zhao B, Shen Y, Henry K, Devlin JW, Murphy DJ, Smith SE, Murray B, Rowe S, Sikora A

Citation: Zhao B, Shen Y, Henry K, et al. A Data-Driven Medication Regimen Complexity Score for Critically Ill Patients: MRC-ICU 2.0. Pharmacotherapy. 2026;46(8):e70185. doi:10.1002/phar.70185

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →